Martin P. Schrama

Martin P. Schrama has no picture

Martin P. Schrama is a Senior Associate in Stark & Stark's Litigation Group. Mr. Schrama has extensive experience litigating on both the trial and appellate levels of the Superior Court of New Jersey, District Court of New Jersey and Supreme Court of New York, as well as numerous other jurisdictions throughout the nation in a pro hac vice capacity. Mr. Schrama focuses his practice on large-scale complex litigation, with a concentration in construction, intellectual property, insurance coverage, securities and class action litigation.


Articles By This Author

Claims against the makers of YAZ®, Yasmin® and Ocella® Will Be Consolidated Before Judge Moss in Philadelphia County, Pennsylvania

no picture

A large number of claims against the makers of defective birth control products, YAZ®, Yasmin® and Ocella®, for injuries ranging from internal organ damage to deep vein thrombosis have been designated as Mass Tort cases in state court, to be consolidated for case management and discovery purposes before Judge Moss in Philadelphia County, Pennsylvania. In the Mass Tort, counsel recently argued before Judge Moss regarding discovery issues. 

Defendants seek information on Plaintiffs’ use of any forms of contraceptive devices or medications.  Plaintiffs object to providing such information, as it would force minor Plaintiffs to reveal their sexual history, thus discouraging Plaintiffs from proceeding with litigation. Plaintiffs also argue information, such as the use of condoms, is not relevant to the injuries suffered allegedly from the use of YAZ®, Yasmin® and Ocella®.  Those discovery issues remain to be decided.

If you, or someone you know, has suffered injuries as a result of taking YAZ®, Yasmin® or Ocella®) contact one of Stark & Stark’s Mass Tort Attorneys today for a free case review.

YAZ®, Yasmin® and Ocella® Cases Designated as Multidistrict Litigation in Federal Courts

no picture

Plaintiffs have brought claims against the makers of YAZ®, Yasmin® and Ocella®, for injuries ranging from internal organ damage (including gallbladder damage), to deep vein thrombosis (or blood clots), stroke, heart attack, myocardial infarction and pulmonary embolism.

A large number of such cases have been designated as Multidistrict Litigation (MDL) cases in the federal courts, to be consolidated for case management and discovery purposes before Judge Herndon the United States District Court for the Southern District of Illinois. In the MDL, on November 12, 2009, the Court appointed attorneys to act as Defendants’ Lead and Liason Counsel, as well as Plaintiffs’ Steering Committee. These select attorneys will be primarily responsible for conducting litigation activities for the consolidated cases.

Stark & Stark’s Mass Tort/Pharmaceutical Litigation Team pursues claims throughout the nation against drug manufacturers, so they can be held accountable when the drugs they market are proven to be defective. If you feel you, or someone you know, have experienced any side-effects from taking YAZ® or Yasmin® contact Stark & Stark to speak to one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the YAZ®, Yasmin® or Ocella® manufacturers.

What is the status of currently pending litigation against YAZ® manufacturers?

no picture

Studies have shown that the ingredients contained in YAZ®, Yasmin® and Ocella® (including the synthetic progestin, drospirenone), have been linked to various forms of internal organ damage (including gallbladder damage), as well as deep vein thrombosis, or blood clots. These blood clots can form in the deep veins of the legs, pelvis, or arms causing extreme pain. It has been found that if the clot dislodges it can lead to sudden, and many times fatal, stroke, heart attack, myocardial infarction or pulmonary embolism.

 

Within the past month, a large number of cases against Bayer HealthCare Pharmaceuticals, the manufacturers of YAZ® and Yasmin®, have been designated as Mass Tort or Multidistrict Litigation (MDL) cases. Mass Tort cases (in State courts) and MDL’s (in federal courts) are methods of organizing and managing cases involving the same or similar injuries and common defendants, in an expedient, cost-effective manner that better enables the plaintiffs to pursue their claims. The Mass Tort cases will be consolidated for case management and discovery purposes before Judge Moss in Philadelphia County, Pennsylvania. The MDL cases will be consolidated for case management and discovery purposes before the Judge Herndon the United States District Court for the Southern District of Illinois.

 

Stark & Stark’s Mass Tort/Pharmaceutical Litigation Team pursues claims throughout the nation against drug manufacturers, so they can be held accountable when the drugs they market are proven to be defective or cause catastrophic injury to the people who use them. If you feel you have experienced any side-effects from taking YAZ® or Yasmin® (or the generic brand, Ocella®, which is marketed and distributed by Barr Laboratories), you can contact Stark & Stark and speak to one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the YAZ®, Yasmin® or Ocella® manufacturers.

Defendants in NuvaRing® Litigation Files Motion To Dismiss Plaintiff's Claims

no picture

As we have discussed in previous posts, NuvaRing®, the combined contraceptive vaginal ring that is supposed to provide month-long birth control, is currently involved in a Multi-District Litigation (“MDL”) in the United States District Court for the Eastern District of Missouri.

Recently, defendants filed numerous motions to dismiss certain plaintiff’s claims for failure to provide a timely or complete “Plaintiff Fact Sheet” (also known as a “PFS”). In pharmaceutical cases with Mass Tort or Multi-District Litigation designations, plaintiffs are required to submit a detailed PFS. The PFS requires the plaintiff to supply medical, liability and general background information within a specified time period, usually subject to periodic updating and revision. The PFS is instrumental in permitting both parties, as well as the Court, to choose bellwether cases for case specific discovery and trial. While defendants’ counsel invariably submit that a broad PFS is especially crucial to determine the defenses to a particular plaintiff’s claims, plaintiffs’ counsel must make certain that the PFS is sufficiently circumscribed so as not to be particularly burdensome to the plaintiffs. Accordingly, there is a constant tension between the parties as to the timing and content of the PFS’s, usually culminating in similar protracted motion practice throughout the litigation.

Case Management Conferences Held in NuvaRing® Litigation

no picture

In a recent blog post, Kevin Hart discussed the recent status of NuvaRing® litigation in Missouri. The cases in the Eastern District of Missouri are at the beginning of the discovery period.  A case management conference was held on July 21, 2009, where certain initial motions and conferences were discussed.  A case management conference was also held in Bergen County, New Jersey on June 5, 2009.  The cases, which are being managed together as a mass tort, are currently in the initial stages of discovery.  Plaintiff Fact Sheets are due August 1, 2009, and discovery should last at least through the end of 2009. 


Should you feel that you have suffered injury due to NuvaRing® use, the Stark & Stark Mass Tort/Pharmaceutical Litigation Team will be happy to review the circumstances of your NuvaRing® injury at no cost or obligation to you. Please fill out the form below for a free evaluation, or further information, from one of our experienced Mass Tort attorneys.

What is the status of currently pending litigation against bisphosphonate manufacturers?

no picture

Currently, a large number of cases against bisphosphonate manufacturers have been designated as Mass Tort or Multidistrict Litigation (MDL) cases. Mass Tort cases (in State courts) and MDL’s (in federal courts) are methods of organizing and managing cases involving the same or similar injuries and common defendants. These methods of case management offer an expedient, cost-effective manner for the plaintiffs to pursue their claims.

Stark & Stark’s Mass Tort/Pharmaceutical Litigation Team pursues claims against drug manufacturers so they can be held accountable when the drugs they market are proven to be defective or cause catastrophic injury to the people who use them. If you feel you have experienced any of the above side-effects from taking bisphosphonates, you can contact Stark & Stark and speak to one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against bisphosphonate manufacturers.
 

What are the possible side-effects of bisphosphonate treatment?

no picture

Studies show that the most commonly reported side-effects of bisphosphonate treatment are: 1) Osteonecrosis of the Jaw; and 2) low-trauma bone fractures.

What is Osteonecrosis of the Jaw?
Studies show that Osteonecrosis of the Jaw (ONJ) or Bisphosphonate Osteonecrosis of the Jaw (BONJ) is a disease where the jawbone does not heal from injury. This disease has also been known as Dead Jaw, Fossy Jaw or Phossy Jaw. Usually, the disease is prefaced by a simple dental procedure or other trauma to the jawbone. Thereafter, the jaw quickly becomes infected and all or a portion of the jawbone can actually die and/or fracture and be painfully thrust through the skin and gums.


What are low-trauma bone fractures?
Studies show that low-trauma bone fractures generally occur as a result of a fall from standing height or less, where the bone breaks in an unusual, horizontal pattern. Such fractures have been found to generally occur in the femur (thigh) bone. However, bone necrosis and bone brittleness have also been reported to have been found, though much more rarely, in other parts of the body.

What are bisphosphonates?

no picture

Bisphosphonates are a class of drugs that drug companies claim promote bone regeneration. Bisphosphonates are commonly sold under various brand names including Fosamax®, Actonel®, Aredia® and Zometa®.

 

These drugs are manufactured by pharmaceutical companies such as Merck, Novartis, Proctor & Gamble and Sanofi-Aventis. Bisphosphonates are used to treat, among other things, osteoporosis, bone metastasis during cancer treatment, osteoarthritis and other conditions that feature bone fragility. Studies show that bisphosphonate treatment can cause severe side-effects including Osteonecrosis of the Jaw and low-trauma bone fractures.

 

NuvaRing® Claims Become the Subject of Multi-District Litigation and Mass Tort Treatment

no picture

NuvaRing® is purported to be a once-a-month, combined contraceptive vaginal ring that provides month-long birth control by emitting a continuous dose of estrogen and progestin for 21 days. NuvaRing® is manufactured by Organon and Akzo Nobel (now divisions of Schering Plough).

 

Studies have shown that NuvaRing® has been found to carry more severe side-effects than its oral contraceptive counterparts. This disparity in the levels of reported side-effects has been attributed to the direct method of hormone introduction. Studies also show that the major side-effect of NuvaRing® is deep vein thrombosis, or blood clots. These blood clots form in the deep veins of the legs, pelvis, or arms causing major discomfort. It has been found that, if the clot dislodges, it can lead to sudden, and many times fatal, stroke, heart attack, myocardial infarction or pulmonary embolism.

 

Currently, NuvaRing® claims are the subject of a Multi-District Litigation in the United States District Court for the Eastern District of Missouri, having been consolidated for discovery purposes in August of 2008. More recently, NuvaRing® claims have been selected for Mass Tort treatment in the New Jersey Superior Court, Bergen County.

Proper Registration of Fabric Dresses Sufficient to Defeat Fraud on the Copyright Office Claims

no picture
Deposits with the copyright office of pictures depicting dress designs, as opposed to specimens of the actual fabric designs, are usually sufficient to protect those designs.  See Blue Fish Clothing, Inc. v. Kat Prints, 1991 WL 71113 at *3 (E.D.Pa. 1991) (Designs displayed in clothing catalogs properly registered); see, also, Winfield Collection, Ltd. v. Gemmy Industries, Corp., 147 Fed.Appx. 547 (6th Cir. 2005) (citing King Features Syndicate v. Fleischer, 299 F. 533 (2d Cir.1924); Geisel v. Poynter Prods. Inc., 295 F.Supp. 331 (S.D.N.Y. 1968); Fleischer Studios, Inc. v. Ralph A. Freundlich, Inc., 5 F.Supp. 808 (S.D.N.Y. 1934)) (copyright protection for two-dimensional photographs or drawings encompasses three-dimensional depictions that are substantially similar).


A party seeking to establish fraud on the copyright office in order to rebut the presumption of copyright validity of a registered dress design, bears the heavy burden of proving deliberate misrepresentation (This same standard is applied for both the copyright application as well as the deposit accompanying the application.  See Data General Corp. v. Grumman Systems Support Corp., 36 F.3d 1147, 1163 (1st Cir. 1994). See Chere Amie, Inc. v. Windstar Apparel, Corp., 191 F.Supp.2d 343, 350-51 (S.D.N.Y. 2001) (citing Whimsicality, Inc. v. Rubie's Costume Co., 891 F.2d 452, 455 (2d Cir.1989); Eckes v. Card Prices Update, 736 F.2d 859, 861-62 (2d Cir.1984) (fraud on the copyright office occurs only when there is a “knowing failure to advise the copyright office of facts which might have occasioned a rejection of the application”); Santrayall v. Burrell, 993 F.Supp. 173, 176 (S.D.N.Y.1998) (the affirmative defense of fraud requires proof of deliberate misrepresentation to overcome the presumption of validity)).


Mere mistake or inadvertence in the application process is not sufficient to challenge the validity of a copyright registration.  See Imperial Laces Inc. v. Westchester Lace Inc., 1998 WL 830630 (S.D.N.Y. 1998).  In Imperial Laces, the plaintiff filed a copyright application with the copyright office claiming a copyright on lace design No. 8191 and identifying itself as the author of the design. However, plaintiff failed to indicate in the designated portion of the application that design No. 8191 was a derivative work based upon lace design No. 5725.  Id.  The application was signed by plaintiff’s vice president, as the authorized agent for plaintiff, who did not read the application before signing it.  Id.  The court found that:
Although required to do so, Imperial failed to identify lace design No. 8191 as a derivative work on its copyright application. As this appears to have been the result of mere inadvertence rather than fraud, however, this omission in no way invalidates Imperial's copyright registration. See Eckes v. Card Prices Update, 736 F.2d 859, 861-62 (2d Cir.1984); Harrison/Erickson, Inc. v. Chicago Bulls Ltd. Partnership, 1991 WL 51118, at *5 (S.D.N.Y. 1991).

Id. at note 4.
   

This requirement of scienter on the part of the applicant in proving fraud on the copyright office was similarly addressed in M.S.R. Imports, Inc. v. R.E. Greenspan Co., Inc., 1983 WL 1778 (E.D.Pa. 1983), which held:
Mr. Rodack testified at trial that, since he believed he had designed the wagons himself based on his own original ideas, there was nothing ‘preexisting’ to report. He may have been entirely incorrect in his narrow reading of the term ‘preexisting,’ but this does not establish intentional or purposeful withholding of information.

Defendant offered nothing to refute Mr. Rodack's claim of lack of understanding of the requirements of section 6 of the application, except the fact that Mr. Rodack had prepared numerous applications in the past. This in itself is insufficient to prove fraudulent conduct or the necessary scienter to warrant invalidation of the copyrights.


Id. at *9 (citations omitted) see, also, Sunham Home Fashions, LLC v. Pem-America, Inc., 2002 WL 31834477 at *5 (S.D.N.Y. 2002) (Manufacturer committed inadvertent error, rather than knowing fraud, on copyright office in falsely designating quilt designs as works made for hire, when it had employees in its design department who did not understand legal terms fill out copyright applications, and thus false designation did not destroy presumption of validity arising from certificates).


Thus, deposits with the copyright office of pictures depicting dress designs are usually sufficient to protect those designs, and a claimant asserting fraud on the copyright office emanating from such deposits bears a heavy burden.